抗PRRSV双功能单链抗体基因的构建、序列分析及蛋白结构预测

为构建抗PRRSV与抗人红细胞单链抗体(2E8-Sc Fv)融合的双功能单链抗体基因并预测其结构和功能,本研究以PRRSV杂交瘤细胞株为模板,通过RT-PCR和SOE-PCR构建PRRSV-Sc Fv基因,将其重组到2E8-Sc Fv C端构建双功能单链抗体基因并测序分析,利用生物信息学软件预测其结构功能。结果显示,成功获得长735 bp的PRRSV-Sc Fv基因,由Linker、VH和VL组成,VH、VL均含明确的CDR和FR区及特征性Cys,与多种鼠源Sc Fv基因高度同源,具有重组功能性鼠源抗体可变区特征,与2E8融合后形成全长1 470 bp的2E8-PRRSV-Sc Fv基因。经生物信息学分析,融合基因编码490个氨基酸,亲水性评估值为-0.365,为亲水性蛋白;结构预测分析显示,其存在丰富的二级结构,可折叠形成含有多个沟槽结构的空间构象,利于抗原的结合,理论上具有良好的抗原结合活性。本研究成功构建抗PRRSV双功能单链抗体基因并对其编码的蛋白质结构进行了预测,为今后进行融合蛋白的表达及最终研究PRRSV抗原快速检测方法奠定基础。     

抗炭疽保护性抗原单克隆抗体可变区基因的克隆及序列分析

目的:克隆并分析抗重组炭疽芽孢杆菌保护性抗原(rPA)单克隆抗体4B2、5E1和2A8轻、重链可变区基因。方法:从分泌抗rPA特异性单抗的杂交瘤细胞株4B2、5E1和2A8中提取总RNA;利用RT-PCR技术克隆抗rPA单抗4B2、5E1和2A8的VL、VH基因,并将其连入pMD18-T载体中进行测序分析。结果:4B2VL基因全长378bp,VH基因全长414bp;5E1VL基因全长420bp,VH基因全长426bp;2A8VL基因全长384bp,VH基因全长342bp。通过分析,这些基因均符合小鼠IgGV区基因的特征,含有4个框架区、3个抗原互补决定区,而且抗体特征性的半胱氨酸残基的数量和位置也正确。结论:克隆了抗rPA单抗4B2、5E1和2A8的VL、VH基因,为下一步构建多种形式的基因工程抗体奠定了良好的基础。     

抗A型产气荚膜梭菌α毒素单链抗体基因的克隆、表达及其生物学活性(英文)

应用RT PCR技术 ,从分泌具有中和活性的抗A型产气荚膜梭菌α毒素单克隆抗体 (McAb)的杂交瘤细胞株 1A8中 ,分别扩增出抗体VH 和VL 基因 ,用linker (Gly4Ser) 3 基因 ,将VH 和VL 基因连接成单链抗体 (ScFv)基因 ,并将其克隆至pGEM T载体中 .经核苷酸序列分析证实 ,VH 和VL 基因及linker基因拼接正确 ,ScFv 1A8基因全长为 72 6bp ,编码2 4 2个氨基酸 ,VH 和VL 基因符合功能性重排的鼠抗体可变区基因特征 ,分别属于鼠免疫球蛋白重链Ⅱ (A)和轻链κⅣ家簇 .将ScFv 1A8基因克隆至表达载体pHOG2 1中 ,构建了重组质粒pHOG 1A8,然后转化至受体菌XL1 BLUE中 ,得到重组菌株XL1 BLUE (pHOG 1A8) .ELISA检测和SDS PAGE分析表明 :经IPTG诱导后所表达的目的蛋白存在于重组菌株XL1 BLUE (pHOG 1A8)的胞周质中 .经薄层扫描分析 :重组菌株XL1 BLUE(pHOG 1A8)的蛋白表达产物占菌体可溶性蛋白的 1 2 % ,其相对分子量约为 31kD .ScFv的生物学活性研究表明 ,ScFv蛋白不但具有中和磷脂酶C的活性 ,而且还能够对致死性腹腔攻击的小鼠产生良好的被动保护作用     

抗鳗弧菌独特型单克隆抗体dsFv的构建及其噬菌体表面呈现

抗鳗弧菌独特型单克隆抗体 1E10是能够模拟鳗弧菌的保护性表位 ,可以作为疫苗使用的一种单克隆抗体 .利用基因工程抗体技术从抗鳗弧菌独特型单克隆抗体杂交瘤细胞株 1E10中克隆出抗体的重链及轻链可变区基因 (VH 和VL) .通过定点突变技术将VH4 4和VL10 5突变为半胱氨酸并且连接到噬菌体表达载体pCANTAB5E中 ,突变后的VH 和VL 基因位于cpⅢ先导序列和cpⅢ基因之间 ,在LacZ启动子调控之下 ,以融合蛋白的形式被导入细胞间隙 ,依靠链间二硫键组装成二硫键稳定型Fv抗体 (dsFv) .加入辅助噬菌体M13K0 7后 ,dsFv以融合蛋白的形式表达在噬菌体表面 .ELISA测定显示 :dsFv噬菌体能够与抗原结合并且这种结合呈噬菌体浓度依赖 .结果表明 :成功构建出了抗鳗弧菌独特型单克隆抗体dsFv基因并使其在噬菌体表面获得了正确呈现 .该dsFv噬菌体有望成为新一代基因工程疫苗用于预防鱼类鳗弧菌感染     

Ⅱ型志贺毒素单克隆抗体可变区基因克隆及单链抗体的表达和功能鉴定

目的从分泌抗肠出血性大肠埃希菌Ⅱ型志贺毒素中和单克隆抗体杂交瘤细胞株S2C4中克隆抗体可变区基因,构建单链抗体（ScFv）,进行原核表达,并对其功能进行鉴定。方法从杂交瘤细胞株S2C4中提取总RNA,逆转录成cDNA。在cDNA3’-OH末端添加poly．G。PCR扩增包括5’非翻译区和信号肽序列在内的抗体重、轻链可变区基因VH和VL,PCR产物装入T—A载体测序。根据测序结果,设计引物分别扩增VH和VL编码区,再通过重叠PCR,在VH和VL．编码区基因之间引入连接链,构建Scn基因,并克隆到表达载体pComb3xSS中。重组载体导入E．coliTop10F’进行表达,重组蛋白经纯化后,分别用ELISA和动物保护性实验鉴定其生物学活性。结果VH和VL编码区基因全长分别为396bp和378bp,ScFv基因能在大肠埃希菌中高效表达,表达产物的分子量为34000,用NiSO4亲和层析柱成功纯化。功能性实验表明纯化的重组蛋白可以与Stx2毒素有效结合,能保护动物抵御毒素分子的攻击。结论成功地克隆S2C4单抗可变区基因,并构建、表达其单链抗体ScFv,为下一步进行该抗体人源化奠定实验基础。     

一株针对人EGFR的单链抗体克隆与哺乳细胞表达

目的:制备特异性抗人表皮生长因子受体(EGFR)的单链抗体(sc Fv),鉴定其生物学活性,为进一步研究基于单链抗体的免疫治疗奠定基础。方法:从分泌抗人EGFR单克隆抗体的杂交瘤细胞系提取总RNA,利用5'RACE技术扩增轻链和重链可变区(VL、VH)基因,构建具有VL、VH基因的单链抗体基因,并将构建的单链抗体基因克隆到真核细胞表达载体pc DNA3.1中进行表达和鉴定。ELISA鉴定单链抗体对抗原的特异性;Fortebio检测抗原抗体间的亲和力,流式细胞术检测单链抗体结合肺癌细胞系天然EGFR的功能活性。结果:获得唯一的轻重链可变区序列VL、VH,成功构建EGFR-sc Fv,特异性与天然EGFR蛋白结合,亲和力达3.22×10-9mol/L。结论:成功构建了抗人EGFR单链抗体,为肺癌免疫导向治疗研究奠定了基础。     

入源中和性抗甲型肝炎病毒抗体Fab段基因的序列分析及可溶性表达

在用噬菌体表面呈现系统获得人源抗甲型肝炎(甲肝)病毒中和性基因工程Fab抗体的基础上,对所获得的4株中和性Fab抗体轻重链可变区基因进行了序列分析、可溶性表达及生物学特性鉴定.4株Fab抗体重链可变区拥有99%同源的核苷酸序列和相同的CDR区氨基酸序列,属于VHⅢ基因家族.而轻链可变区核苷酸序列同源性为95%和相似的CDR区氨基酸序列,属于VL5基因家族.这些重组抗体都能与人甲肝恢复期血清及具有中和活性的鼠抗甲肝单克隆抗体产生竞争抑制反应,表明其针对甲肝病毒结构蛋白上的主要抗原决定簇.     

抗CD5单链抗体基因克隆和表达

以分泌抗CD5单克隆抗体的杂交瘤细胞poly(A) mRNA为模板,通过RTPCR扩增出抗CD5单克隆抗体的重链可变区(VH)和轻链可变区(VL) cDNA片段组装出抗CD5单链抗体(ScFv) cDNA片段。该ScFv片段被克隆到pCANTAB 5E载体上,以E.coli TG1为宿主,进行噬菌体表面呈现。通过Molt4细胞表面分子CD抗原,对噬菌体表面呈现的ScFv进行免疫亲和富集筛选。经细胞ELISA鉴定,得到4株高亲和力克隆。DNA序列分析得知,单链抗体全长732碱基,其中VH为339碱基,VL为300碱基。抗CD5 ScFv在E.coli HB2151中以可溶形式分泌表达,产物主要分布于周质之中,占周质中总蛋白的20%。     

β淀粉样肽单克隆抗体可变区基因的5′RACE扩增及序列分析

目的:克隆并分析抗β淀粉样肽单克隆抗体轻链与重链可变区基因。方法:从分泌抗β淀粉样肽单克隆抗体的杂交瘤细胞株A8中提取总RNA,根据恒定区序列设计基因特异性引物,通过5′RACE法扩增抗体的轻链和重链可变区基因,测定并分析可变区基因序列,并克隆入pMD18-T载体。结果:重链可变区基因序列全长450bp,编码150个氨基酸残基;轻链可变区基因序列全长429bp,编码143个氨基酸残基。在GeneBank中对氨基酸序列进行比对分析,二者均符合小鼠IgG可变区基因的特征。根据Kabat法则对A8抗体轻链和重链可变区氨基酸序列基因进行分析并确定了3个抗原互补决定区(CDR)、4个框架区(FR)和信号肽。结论:通过5′RACE法得到了抗β淀粉样肽单克隆抗体轻链与重链可变区基因,为进一步研究抗体三维结构,以及对该抗体进行人源化改造奠定了基础。     

抗人血管内皮生长因子单链抗体基因的构建、表达及活性鉴定

鼠单克隆抗体E11能与人血管内皮生长因子(VEGF)特异结合,已用于临床检测恶性肿瘤细胞VEGF的表达,并初步证明其体内抑瘤活性。为便于大规模生产,特进行基因工程改造,构建小分子的单链抗体(scFv)。首先通过逆转录及多聚酶链式反应(PCR),分离并克隆E11的可变区基因。经测序表明,E11轻链可变区(VL)基因全长333bp,编码111个氨基酸,归属小鼠轻链可变区基因第Ⅲ亚组。重链可变区VH基因全长369bp,编码123个氨基酸,归属小鼠重链可变区基因Ⅱ(A)亚组。然后用一编码亲水性多肽接头的DNA片断将E11单抗轻、重链可变区基因连接,构建表达质粒pET-15YV,在大肠杆菌BL21(DE3)中进行表达。表达产物(包含体)经变性及复性后,用免疫组化法检测该单链抗体结合抗原(颊癌)能力。对颊癌组织检测的结果表明,基因工程抗体scFv与亲代抗体一样,具有较高的组织特异性。本研究获得的抗人VEGF单链抗体具有潜在的临床价值,为肿瘤放射免疫显像及以血管为靶标的抗血管生成治疗奠定了基础。     

抗人前列腺干细胞抗原单克隆抗体可变区基因的5＇RACE扩增及序列分析

目的：克隆并分析抗人前列腺干细胞抗原单克隆抗体轻链和重链的可变区基因。方法：从分泌抗人前列腺干细胞抗原单克隆抗体的杂交瘤细胞株中提取总RNA,根据小鼠IgG恒定区序列设计特异性引物,通过5’RACE法扩增其轻链和重链的可变区基因,克隆入pMD18-T载体,测序并分析其可变区序列。结果：3株抗人前列腺干细胞抗原单克隆抗体的重链可变区基因序列全长均为423bp,编码141个氨基酸残基;轻链可变区基因序列全长均为393bp,编码131个氨基酸残基;在GenBank中对氨基酸序列进行比对分析,均符合小鼠IgG可变区基因的特征;根据Kabat法则对3株抗体轻链和重链可变区氨基酸序列进行分析,确定了3个抗原互补决定区、4个框架区和前导肽。结论：通过5＇RACE法得到了3株抗人前列腺干细胞抗原单克隆抗体轻链与重链可变区基因,为进一步研究抗体三维结构、人源化改造奠定了基础。     

抗人黑色素瘤单链抗体基因的克隆和分泌型表达

应用ＲＴ－ＰＣＲ技术从分泌抗人黑色素瘤单克隆抗体的杂交瘤细胞ＨＢ８７６０中克隆了抗体轻、重链可变区基因,然后用（Ｇｌｙ４Ｓｅｒ）３连接肽基因将ＶＨ、ＶＬ连接成ＳｃＦｖ基因,并进行了序列测定．计算机分析表明ＶＨ,ＶＬ均符合小鼠抗体可变区的特征,为功能性重排的抗体可变区基因．ＶＨ、ＶＬ、ｌｉｎｋｅｒ拼接正确．ＳｃＦｖ基因全长７２９ｂｐ,其中ＶＨ基因长３６０ｂｐ,编码１２０个氨基酸,ＶＬ基因长３２４ｂｐ,编码１０８个氨基酸．在噬菌粒表达载体ｐＣＡＮＴＡＢ５Ｅ中表达了可溶性的ＳｃＦｖ蛋白,表达产物经流式细胞仪检测可特异地与黑色素瘤细胞结合,不与肝癌、胃癌及良性黑痣细胞结合     

抗甜菜坏死黄脉病毒单链抗体表达载体的构建及其表达

用ＰＣＲ方法以分泌抗甜菜坏死黄脉病毒（ＢＮＹＶＶ）单克隆抗体的杂交瘤细胞的基因组为模板,扩增了编码ＢＮＹＶＶ单抗的重链可变区（ＶＨ）基因。测序表明,该ＶＨ序列属于小鼠ＩＩ（Ａ）亚类,全长为３６０ｂｐ,编码１２０个氨基酸。将其和先前克隆的轻链基因分别插入到一个含有连接ＶＨ和ＶＬ基因的连接序列的质粒之中,构建成单链抗体（ｓｃＦｖ）基因的表达载体ｐＴＣｓｃＦｖ。将质粒在大肠杆菌中表达,ＥＬＩＳＡ法检测出     

抗A型产气荚膜梭菌α毒素单链抗体基因的克隆和表达

应用RT PCR技术 ,从分泌具有中和活性的抗A型产气荚膜梭菌α毒素单克隆抗体的杂交瘤细胞中 ,扩增出抗体V_H 和V_L 基因 ,连接成ScFv基因 ,并将其克隆至pGEM T载体中构建了重组质粒pXScFv 2E3。经序列分析证实 ,V_H 和V_L 基因及linker基因拼接正确 ,基因全长为 726bp ,编码 242个氨基酸。随后将其定向克隆于表达载体pHOG21,转化至大肠杆菌XL1 BLUE筛选出表达菌株XL1 BLUE(pHOG 2E3)。经ELISA和SDS PAGE分析表明 ,在20℃用IPTG诱导培养时 ,表达的ScFv蛋白占菌体总蛋白的 25 %。并且ScFv基因表达产物能够中和α毒素的磷酯酶C活性     

Complete heavy and light chain variable region sequence of anti-arsonate monoclonal antibodies from BALB/c and A/J mice sharing the 36-60 idiotype are highly homologous

Structural and serologic studies on murine A/J monoclonal anti-arsonate antibodies resulted in the identification of a second idiotype family (Id36-60) in addition to the predominant idiotype family (IdCR). Id36-60, unlike IdCR, is a dominant idiotype in the BALB/c strain but is a "minor" idiotype in the A/J strain. The complete heavy and light chain variable region (VH and VL) amino acid sequences of a representative Id36-60 hybridoma protein from both the A/J and BALB/c strains have been determined. There are only four amino acid sequence differences between the VH of antibody 36-60 (A/J) and antibody 1210.7 (BALB/c). Two of these differences arise from single nucleotide changes in which the A/J and BALB/c Id36-60 VH germline gene sequences differ. The two other differences are the result of somatic mutation in hybridoma protein 36-60. In addition, Id36-60 heavy chains employ the same D and JH3 segments in both strains. The entire Vk2 VL of 36-60 and 1210.7 differ by only two amino acids, suggesting that like the heavy chains, they are derived from highly homologous VL genes. The same Jk segment is used in both antibodies. A comparison of the amino acid sequence data from Id36-60-bearing hybridomas suggests that a heavy chain amino acid difference accounts for the diminished arsonate binding by the 1210.7 hybridoma protein. Because the 1210.7 heavy chain is the unmutated product of the BALB/c VH gene, somatic mutation in VH may be required to enhance Ars affinity in this system.     

抗人大肠癌重组单链抗体的研制

应用重组噬菌体抗体系统制备了重组单链抗体。首先从抗人结肠癌ND-1单抗杂交瘤细胞中提取mRNA,利用反转录多聚酶链反应(RT-PCR)扩增出单抗重链可变区(V_H)及轻链可变区(V_L)片段,再通过连接DNA合成单链抗体可变区片段(ScFv),然后经双酶切后克隆到pCANTAB5E载体中,在E.coliTGI细胞中表达出噬菌体融合蛋白,用抗原阳性噬菌体感染E.coliHB2151细胞,产生单链抗体,该单链抗体既保持了原单抗的特异性,应用上又优于原单抗。     

Nucleotide and translated amino acid sequences of cDNA coding for the variable regions of the light and heavy chains of mouse hybridoma antibodies to blood group A and B substances

This is the first report of nucleotide and translated amino acid sequences of the variable region light (VL) and heavy (VH) chains of mouse monoclonal hybridoma anti-blood group A and B substances, the combining sites of which have been mapped. Monoclonal hybridoma anti-A and anti-B produced in BALB/c mice by immunization with A or B blood group substances, with A1 erythrocytes, and water-soluble blood group A substance or with synthetic B determinants coupled to bovine serum albumin or to O erythrocytes have been characterized immunochemically. To relate the immunochemical properties of the monoclonals to their primary structures, we have cloned and sequenced cDNAs of variable regions of light and heavy chains of two anti-A and two anti-B. The anti-A hybridomas have very similar combining site specificities and have almost identical VH sequences belonging to the J558 germ-line family, but their VL are from different germ-line VK gene families. The two anti-B hybridomas have different combining site specificities and use the same VL which differs completely from the anti-A VL; their VH are derived from different VH germ-line genes belonging to the J606 family. The results suggest that the heavy chains play a major role in determining the specificities of the antibody combining sites, with only minor contribution of VL. Additional sequence data on monoclonal antibodies of defined specificity for blood group substances are needed for further insights into the genetic and structural basis for their specificities.     

Gene cloning, bacterial expression, in vitro refolding, and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg

The murine monoclonal antibody 125E11 is an IgG which recognizes PreS1(21-47) fragment of large hepatitis B surface antigen. It has been successfully used for clinical detection of HBV virion in serum of hepatitis B patients. In present study, the genes of variable region in heavy chain (VH) and light chain (VL) of 125E11 have been cloned. Sequence analysis of cloned VH gene and VL gene showed that they had general characterization of immunoglobin variable region genes. According to Kabat classification, VH gene and VL gene belong to VH10 family, subgroup IIID and Vkappa family subgroup I, respectively. An expression vector of 125E11 single-chain Fv antibody fusion protein, in which VH and VL peptide were connected by a flexible linker (Gly(4)Ser)(3), was constructed. The scFv fusion protein was highly expressed in Escherichia coli mainly in inclusion body form. Using urea and pH gradient gel filtration method, the refolding of scFv was efficiently achieved. The refolding efficiency reached about 11% and 2.7 mg refolded scFv was obtained from 1L of culture. The binding activity and specificity of 125E11 scFv against PreS1(21-47)-containing antigen were also analyzed.     

Functional Fv fragment of an antibody specific for CD28: Fv-mediated co-stimulation of T cells

The most predominant co-stimulation pathway, which is critical for T cell activation and proliferation, is the CD28-B7 pathway. The anti-CD28 monoclonal antibody (mAb) also provides a co-stimulatory signal to T cells. In order to construct a functional Fv fragment (complex of VH and VL domains) of anti-CD28 antibody using a bacterial expression system, cDNA encoding the variable regions of immunoglobulin from 15E8 hybridoma cells was cloned and expressed in Escherichia coli. The Fv fragment was obtained as a soluble protein from the periplasmic fraction and showed a binding pattern similar to parental IgG. The Fv fragment induced proliferation of peripheral blood mononuclear cells in the presence of anti-CD3 or anti-CD2 mAb and enhanced anti-tumor activity of anti-MUC1x(anti)-CD3 bispecific antibody when tested with lymphokine-activated killer cells with T cell phenotype. Thus, the anti-CD28 Fv fragment will be promising not only for the study of co-stimulation, but also for cancer immunotherapy.